Khiron Life Sciences Corp. News Releases

Khiron Life Sciences Announces Closing of the Sale of Its European Business

Fri, 17 Nov 2023 19:48:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 17, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQX: KHRNF) ("Khiron" or the "Company") is pleased to announce that the Company has completed the sale of its European subsidiaries, being Khiron Europe GmbH ("Khiron Europe"), Zerenia Clinics Limited ("Zerenia UK"), PharmaDrug Production GmbH ("Pharmadrug"), Khiron Life Sciences UK Limited ("Khiron UK") and Khiron Life Sciences Spain SL ("Khiron Spain", and collectively with Khiron Europe,...

Khiron Life Sciences Announces Update to the Proposed Sale of Its European Business

Thu, 16 Nov 2023 18:42:00 -0500

Toronto, Ontario--(Newsfile Corp. - November 16, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTC Pink: KHRNF) ("Khiron" or the "Company") today announced that the Company and 2518542 Alberta Ltd., a company controlled by Avonlea Drewry Holdings Inc. (the "Purchaser"), have entered into an amended and restated share purchase agreement (the "Restated Purchase Agreement") dated November 15, 2023, providing for the purchase and sale of the Company's European subsidiaries. Under the terms of the...

Khiron Life Sciences Agrees to $500,000 Secured Deposit

Mon, 05 Jun 2023 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - June 5, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") announced today that the Company has agreed to a $500,000 non-interesting bearing refundable deposit from 2518542 Alberta Ltd. ("251"), a company controlled by Avonlea-Drewry Holdings Inc., to be secured by all of Khiron's present and after-acquired property pursuant to a general security agreement and a pledge of Khiron's shares in its subsidiaries, Pharmadrug...

Medical First: Germany Strengthens Reimbursement of Medical Cannabis

Tue, 25 Apr 2023 08:30:00 -0400

On 16 March 2023, after five years of observational data collection the German Federal Joint Committee (G-BA) decided on the future regulations that will govern the prescription of medical cannabis as a benefit of the statutory health insuranceAfter several months of discussions and thoroughly analyzing the data, the G-BA passed regulations that ensure patient care with medical cannabis and coverage by statutory health insuranceGermany is the largest and fastest growing medical cannabis market...

Khiron Completes First Phase of Business Optimization

Thu, 20 Apr 2023 16:41:00 -0400

First phase of optimization was focused on streamlining Colombian operations, resulting in a moving forward annualized cost reduction of CAD 5.0 million, representing overall cost savings of more than 45% compared to 20221.Khiron has completed the wind down of its Colombian cultivation and extraction activities, to focus on its clinics business and its high-margin B2C medical cannabis model in Colombia.Similar to the Company’s European production model, Khiron Colombia will outsource the...

Khiron Life Sciences Announces Closing of Marketed Offering Including Full Exercise of Over-Allotment Option

Tue, 04 Apr 2023 09:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - April 4, 2023) - Khiron Life Sciences Corp. (TSXV: KHRN) (OTCQB: KHRNF) ("Khiron" or the "Company") is pleased to announce that it has closed today its previously announced marketed public offering of units of the Company ("Units"), including the exercise in full of the over-allotment option (the "Offering").A total of 13,800,000 Units were sold at a price of $0.05 per Unit (the "Offering Price") for aggregate gross proceeds of $690,000. The Offering was led...